Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) classified as a cognitive research compound and recognised as an ACTH 4-10 analogue. This neuropeptide has garnered significant attention in neuroscience research for its multifaceted mechanisms of action and potential applications in cognitive enhancement studies. The primary mechanism of action involves modulation of brain-derived neurotrophic factor (BDNF) expression and other neurotrophins, which are critical for neuronal survival, growth, and synaptic plasticity. Research indicates that Semax enhances the availability of key neurotransmitters including dopamine and serotonin, both essential for cognitive processes such as attention, memory, and mood regulation. Studies demonstrate that Semax inhibits the breakdown of enkephalins, endogenous peptides that regulate pain perception and stress responses. This mechanism may contribute to its observed anxiolytic properties in research models. Additionally, the literature reports potential improvements in cerebral blood flow, which could underlie its cognitive-enhancing effects. Research applications focus on memory retention and recall enhancement, attention and focus improvement, and neuroprotective properties following brain injury in experimental models. Studies indicate potential for reducing anxiety and depression-like behaviours whilst promoting neurological recovery. The evidence base consists primarily of Russian clinical trials suggesting cognitive improvements, particularly in neurological conditions. However, researchers note that these studies often lack rigorous controls, and the evidence grade is classified as B. More high-quality, placebo-controlled trials are needed to fully establish the compound's research potential. The regulatory landscape is evolving, with FDA Category 2 reclassification to Category 1 expected by February 2026.